BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/19/2017 11:33:54 AM | Browse: 1402 | Download: 2842
Publication Name World Journal of Gastroenterology
Manuscript ID 32406
Country Australia
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Basic Study
Article Title cytoplasmic domain of tissue factor promotes liver fibrosis in mice
Manuscript Source Invited Manuscript
All Author List Virginia Knight, Dinushka Lourenz, Jorge Tchongue, Jeanne Correia, Peter Tipping and William Sievert
Funding Agency and Grant Number
Corresponding Author William Sievert, MD, Director, Director, Professor, Gastroenterology and Hepatology Unit, Monash Health, 246 Clayton Road, Melbourne 3168, Victoria, Australia. william.sievert@monash.edu
Key Words Tissue factor; protease activated receptor; Hepatic stellate cell; liver fibrosis; macrophage
Core Tip No effective anti-fibrotic therapies are avail­able for patients with cirrhosis. PAR-2, a receptor that activates coagulation and inflammation, promotes hepatic fibrosis; whether tissue factor (TF), the primary initiator of the coagulation cascade, affects hepatic fibrosis is unknown. We found that deletion of the TF cytoplasmic domain reduces fibrosis through an effect on hepatic stellate cell activation, possibly mediated through reduced hepatic macrophage activation. Currently available direct thrombin inhibitors may be useful in preventing hepatic fibrosis while therapeutic targeting of the cytoplasmic domain of TF may be useful in patients with advanced liver disease, as its deletion does not alter coagulation.
Publish Date 2017-08-19 11:33
Citation Knight V, Lourensz D, Tchongue J, Correia J, Tipping P, Sievert W. cytoplasmic domain of tissue factor promotes liver fibrosis in mice. World J Gastroenterol 2017; 23(31): 5692-5699
URL http://www.wjgnet.com/1007-9327/full/v23/i31/5692.htm
DOI http://dx.doi.org/10.3748/wjg.v23.i31.5692
Full Article (PDF) WJG-23-5692.pdf
Full Article (Word) WJG-23-5692.doc